Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Other Accumulated Expenses: 2013-2020

Historic Other Accumulated Expenses for Larimar Therapeutics (LRMR) over the last 6 years, with Sep 2020 value amounting to $111,000.

  • Larimar Therapeutics' Other Accumulated Expenses was N/A to $111,000 in Q3 2020 from the same period last year, while for Sep 2020 it was $111,000, marking a year-over-year change of. This contributed to the annual value of $508,000 for FY2019, which is 127.80% up from last year.
  • Larimar Therapeutics' Other Accumulated Expenses amounted to $111,000 in Q3 2020, which was down 76.08% from $464,000 recorded in Q2 2020.
  • In the past 5 years, Larimar Therapeutics' Other Accumulated Expenses registered a high of $508,000 during Q4 2019, and its lowest value of $56,000 during Q3 2016.
  • In the last 3 years, Larimar Therapeutics' Other Accumulated Expenses had a median value of $213,000 in 2018 and averaged $259,222.
  • As far as peak fluctuations go, Larimar Therapeutics' Other Accumulated Expenses slumped by 63.36% in 2016, and later spiked by 140.00% in 2018.
  • Over the past 5 years, Larimar Therapeutics' Other Accumulated Expenses (Quarterly) stood at $110,000 in 2016, then declined by 4.55% to $105,000 in 2017, then spiked by 112.38% to $223,000 in 2018, then skyrocketed by 127.80% to $508,000 in 2019, then rose by 11.32% to $111,000 in 2020.
  • Its last three reported values are $111,000 in Q3 2020, $464,000 for Q2 2020, and $236,000 during Q1 2020.